Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200675 | 0.83 | GABRA1 (0.55) | GABRA1GABRB2HTR1ADRD2DRD4 | |
| SCHEMBL3786513 | 0.83 | TAAR1 (0.44) | PNMTALDH1A1TSHRCYP3A4PIK3CA | |
| SCHEMBL5591177 | 0.81 | PNMT (0.62) | PNMTALDH1A1TSHRCYP3A4TAAR1 | |
| SCHEMBL699759 | 0.81 | PNMT (0.44) | PNMTALDH1A1TSHRCYP3A4PIK3CA | |
| SCHEMBL3783958 | 0.79 | TAAR1 (0.41) | PNMTALDH1A1TAAR1 | |
| SCHEMBL21852155 | 0.79 | POLB (0.40) | GABRA1GABRB2HTR1ADRD2DRD4 | |
| Nitrogen SCHEMBL10979594 | 0.78 | GABRA1 (0.50) | GABRA1GABRB2HTR1ADRD2DRD4 | |
| SCHEMBL29565534 | 0.78 | — | — | |
| SCHEMBL39547 | 0.78 | — | — | |
| Ethylene SCHEMBL1818621 | 0.77 | PNMT (0.41) | PNMTALDH1A1TSHRCYP3A4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848351-B1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240408084-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-12 | — | — | US | disclosed |
| US-12162861-B2 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-10 | — | — | US | disclosed |
| US-12097196-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-09-24 | — | — | US | disclosed |
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20220265643-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-08-25 | — | — | US | disclosed |
| US-20220185798-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-06-16 | — | — | US | disclosed |
| US-20220185798-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-06-16 | — | — | US | disclosed |
| US-11337971-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-05-24 | — | — | US | disclosed |
| US-11337971-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-05-24 | — | — | US | disclosed |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-09-17 | — | — | US | disclosed |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-09-17 | — | — | US | disclosed |
| WO-2020055725-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-03-19 | — | — | WO | disclosed |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | SYNBLIA THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2019-09-26 | — | — | US | disclosed |
| EP-3429993-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017160552-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017160552-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | GABRA1 3604/4885GABRB2 3264/4885HTR1A 4727/4885 |
| US-20220185798-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | DRD3, DRD2, SLC6A3 | GABRA1 229/4885GABRB2 331/4885HTR1A 45/4885 |
| US-12162861-B2 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | DRD3, DRD2, SLC6A3 | GABRA1 229/4885GABRB2 331/4885HTR1A 45/4885 |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | DRD3, DRD2, SLC6A3 | GABRA1 229/4885GABRB2 331/4885HTR1A 45/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | GABRA1 991/4885GABRB2 561/4885HTR1A 3657/4885 |
| US-12097196-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | OPRD1, OPRK1, DRD3 | GABRA1 221/4885GABRB2 295/4885HTR1A 54/4885 |
| US-20240408084-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | DRD3, OPRD1, DRD2 | GABRA1 168/4885GABRB2 208/4885HTR1A 65/4885 |
| US-20220265643-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | OPRD1, OPRK1, DRD3 | GABRA1 221/4885GABRB2 295/4885HTR1A 54/4885 |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | GABRA1 3604/4885GABRB2 3264/4885HTR1A 4727/4885 |
| US-11337971-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | OPRD1, OPRK1, DRD3 | GABRA1 221/4885GABRB2 295/4885HTR1A 54/4885 |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | PTPN1, PTPN7, PTPN18 | GABRA1 3604/4885GABRB2 3264/4885HTR1A 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.